Dipal Doshi, CEO at Entrada Therapeutics, Inc. (TRDA), sold 1,900 shares at $18.00 ($34K) on 2024-07-12, disclosed to the SEC on 2024-07-16.
Scheduled sale ($34k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.00 | 300 | $5K | 15.9% |
| 2 | $17.81 | 1,600 | $28K | 84.1% |
| Total | $17.84 avg | 1,900 | $34K | 100% |
| Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |
| TRDA | SELL | 2023-12-22 | $15K | — | Filing → |